keyword
MENU ▼
Read by QxMD icon Read
search

brain tumors pet

keyword
https://www.readbyqxmd.com/read/28937983/-18f-fdopa-standardized-uptake-values-of-brain-tumors-are-not-exclusively-dependent-on-lat1-expression
#1
Bérengère Dadone-Montaudié, Damien Ambrosetti, Maxime Dufour, Jacques Darcourt, Fabien Almairac, John Coyne, Thierry Virolle, Olivier Humbert, Fanny Burel-Vandenbos
[18F]-FDOPA is a labeled amino acid (AA) analog used for positron emission tomography (PET) which is gaining increasing interest in the evaluation of brain tumors (BT). The AA-transporter LAT1 has been shown to be involved in [18F]-FDOPA uptake. The aim of this study was to determine whether the [18F]-FDOPA uptake was correlated with level of LAT1 expression in BT. Twenty-eight BT (including 19 gliomas and 9 metastases) were investigated by [18F]-FDOPA-PET prior to surgery and by anti-LAT1 immunohistochemistry on surgical specimens...
2017: PloS One
https://www.readbyqxmd.com/read/28936429/clinical-pet-mri-in-neurooncology-opportunities-and-challenges-from-a-single-institution-perspective
#2
REVIEW
Lisbeth Marner, Otto M Henriksen, Michael Lundemann, Vibeke Andrée Larsen, Ian Law
PURPOSE: Magnetic resonance imaging (MRI) plays a key role in neurooncology, i.e., for diagnosis, treatment evaluation and detection of recurrence. However, standard MRI cannot always separate malignant tissue from other pathologies or treatment-induced changes. Advanced MRI techniques such as diffusion-weighted imaging, perfusion imaging and spectroscopy show promising results in discriminating malignant from benign lesions. Further, supplemental imaging with amino acid positron emission tomography (PET) has been shown to increase accuracy significantly and is used routinely at an increasing number of sites...
2017: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28922334/common-malignant-brain-tumors-can-18f-fdg-pet-ct-aid-in-differentiation
#3
Nilendu C Purandare, Ameya Puranik, Sneha Shah, Archi Agrawal, Tejpal Gupta, Aliasgar Moiyadi, Prakash Shetty, Epari Shridhar, Rakesh Jalali, Venkatesh Rangarajan
OBJECTIVES: The objectives of this study were to evalute the metabolic characteristics of common malignant space-occupying lesions (SOL) of the brain and to determine the utility of fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT in differentiating between the common types of malignant brain SOL. PATIENTS AND METHODS: All patients with brain SOL who were referred for an F-FDG PET/CT scan by a multidisciplinary team were included in this retrospective study. The metabolic characteristics of the brain lesions in the form of maximum standardized uptake value (SUVmax) along with tumor-to-background activity ratios were determined and differences were compared using nonparametric statistical tests...
September 15, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28913154/pet-ct-imaging-of-the-diapeutic-alkylphosphocholine-analog-124-i-clr1404-in-high-and-low-grade-brain-tumors
#4
Lance T Hall, Benjamin Titz, H Ian Robins, Bryan P Bednarz, Scott B Perlman, Jamey P Weichert, John S Kuo
CLR1404 is a cancer-selective alkyl phosphocholine (APC) analog that can be radiolabeled with (124)I for PET imaging, (131)I for targeted radiotherapy and/or SPECT imaging, or (125)I for targeted radiotherapy. Studies have demonstrated avid CLR1404 uptake and prolonged retention in a broad spectrum of preclinical tumor models. The purpose of this pilot trial was to demonstrate avidity of (124)I-CLR1404 in human brain tumors and develop a framework to evaluate this uptake for use in larger studies. 12 patients (8 men and 4 women; mean age of 43...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28906344/value-of-the-visual-and-semiquantitative-analysis-of-carbon-11-methionine-pet-ct-in-brain-tumors-recurrence-versus-post-therapeutic-changes
#5
Nestor Martínez-Amador, Julio Jiménez-Bonilla, Isabel Martínez-Rodríguez, Maria De Arcocha-Torres, Remedios Quirce, Francisco J Gómez-de la Fuente, Jorge L López-Defilló, Ignacio Banzo
To compare the visual and semiquantitative analysis of carbon-11-methionine (C-MET) PET/computed tomography (CT) images in patients with primary brain tumors and suspected recurrence, persistence, or necrotic post-therapeutic changes. A total of 41 consecutive C-MET-PET/CT scans on 35 (21 men, mean age 44.1±16.6 years) patients were requested for MRI suspicion of recurrent or persistent primary tumor after therapy. The C-MET PET/CT were obtained 20 min after an intravenous injection of 555-740 MBq (15-20 mCi) of C-MET...
September 12, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28903405/uptake-of-psma-ligands-in-normal-tissues-is-dependent-on-tumor-load-in-patients-with-prostate-cancer
#6
Florian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, Stefan Kürpig, Elisabeth Eppard, Charalambos Kotsikopoulos, Nikolaos Liakos, Ralph A Bundschuh, Holger Strunk, Markus Essler
Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load. RESULTS: In patients with high tumor load, SUVmean was reduced to 61.5% in the lacrimal glands, to 56.6% in the parotid glands, to 63.7% in the submandibular glands, to 61.3% in the sublingual glands and to 55.4% in the kidneys (p < 0...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28887599/uptake-of-av-1451-in-meningiomas
#7
Tyler J Bruinsma, Derek R Johnson, Ping Fang, Matthew Senjem, Keith A Josephs, Jennifer L Whitwell, Bradley F Boeve, Mukesh K Pandey, Kejal Kantarci, David T Jones, Prashanthi Vemuri, Melissa Murray, Jonathan Graff-Radford, Christopher G Schwarz, David S Knopman, Ronald C Petersen, Clifford R Jack, Val J Lowe
AIM: AV-1451 is an imaging agent labeled with the positron-emitting radiolabel Fluorine-18. 18F-AV-1451 binds paired helical filament tau (PHF-tau), a pathology related to Alzheimer's disease. In our study of AV-1451 uptake in the brains of cognitively normal subjects, we noted a case of a meningioma with visually significant uptake of AV-1451. OBJECTIVE: We initiated the present retrospective study to further examine cases of meningioma that underwent AV-1451 imaging...
September 8, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28879406/whole-tumor-histogram-analysis-of-the-cerebral-blood-volume-map-tumor-volume-defined-by-11c-methionine-positron-emission-tomography-image-improves-the-diagnostic-accuracy-of-cerebral-glioma-grading
#8
Rongli Wu, Yoshiyuki Watanabe, Atsuko Arisawa, Hiroto Takahashi, Hisashi Tanaka, Yasunori Fujimoto, Tadashi Watabe, Kayako Isohashi, Jun Hatazawa, Noriyuki Tomiyama
PURPOSE: This study aimed to compare the tumor volume definition using conventional magnetic resonance (MR) and 11C-methionine positron emission tomography (MET/PET) images in the differentiation of the pre-operative glioma grade by using whole-tumor histogram analysis of normalized cerebral blood volume (nCBV) maps. MATERIALS AND METHODS: Thirty-four patients with histopathologically proven primary brain low-grade gliomas (n = 15) and high-grade gliomas (n = 19) underwent pre-operative or pre-biopsy MET/PET, fluid-attenuated inversion recovery, dynamic susceptibility contrast perfusion-weighted magnetic resonance imaging, and contrast-enhanced T1-weighted at 3...
September 6, 2017: Japanese Journal of Radiology
https://www.readbyqxmd.com/read/28874539/detection-of-immune-responses-after-immunotherapy-in-glioblastoma-using-pet-and-mri
#9
Joseph P Antonios, Horacio Soto, Richard G Everson, Diana L Moughon, Anthony C Wang, Joey Orpilla, Caius Radu, Benjamin M Ellingson, Jason T Lee, Timothy Cloughesy, Michael E Phelps, Johannes Czernin, Linda M Liau, Robert M Prins
Contrast-enhanced MRI is typically used to follow treatment response and progression in patients with glioblastoma (GBM). However, differentiating tumor progression from pseudoprogression remains a clinical dilemma largely unmitigated by current advances in imaging techniques. Noninvasive imaging techniques capable of distinguishing these two conditions could play an important role in the clinical management of patients with GBM and other brain malignancies. We hypothesized that PET probes for deoxycytidine kinase (dCK) could be used to differentiate immune inflammatory responses from other sources of contrast-enhancement on MRI...
September 5, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28872554/detection-of-non-fdg-avid-residual-sinonasal-malignant-melanoma-in-the-skull-base-with-11c-choline-pet-and-contrast-enhanced-mri
#10
Chunxia Qin, Fan Hu, Maher Mohamad Rajab Arnous, Xiaoli Lan
Primary sinonasal melanoma is a rare disease. We present a case of melanoma in sinuses without abnormal F-FDG activity anywhere in the scanned portion of the body. In further assessment, C-choline PET/CT revealed high activity in the paranasal sinuses, skull base, and adjacent brain, in agreement with the high signal on contrast-enhanced T1-weighted MRI scan, which suggested the residual tumor.
September 1, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28868256/multiparametric-mri-and-18-f-fluorodeoxyglucose-positron-emission-tomography-imaging-is-a-potential-prognostic-imaging-biomarker-in-recurrent-glioblastoma
#11
Comron Hassanzadeh, Yuan James Rao, Anupama Chundury, Jackson Rowe, Maria Rosana Ponisio, Akash Sharma, Michelle Miller-Thomas, Christina I Tsien, Joseph E Ippolito
PURPOSE/OBJECTIVES: Multiparametric advanced MR and [(18)F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging may be important biomarkers for prognosis as well for distinguishing recurrent glioblastoma multiforme (GBM) from treatment-related changes. METHODS/MATERIALS: We retrospectively evaluated 30 patients treated with chemoradiation for GBM and underwent advanced MR and FDG-PET for confirmation of tumor progression. Multiparametric MRI and FDG-PET imaging metrics were evaluated for their association with 6-month overall (OS) and progression-free survival (PFS) based on pathological, radiographic, and clinical criteria...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28863122/a-novel-molecular-agent-for-glioma-angiogenesis-imaging
#12
Chuanwang Miao, Wei Zhao, Shuanghu Yuan, Jinming Yu, Shuqiang Zhao, Li Ma, Dexian Zhang, Xudong Hu
BACKGROUND: Gliomas are rich in blood vessels and are the most primary and malignant type of brain tumor affecting the central nervous system. A few fluorine-18 (F)-labeled imaging agents can be used for imaging of tumor angiogenesis. In the current study, F-labeled recombinant human endostatin (rh-endostatin) was developed and evaluated as a probe for PET imaging of tumor angiogenesis. MATERIALS AND METHODS: F-fluorobenzoyl-endostatin (F-FB-endostatin) was synthesized from radiolabeling of rh-endostatin with N-succinimidyl-4-F-fluorobenzoate produced by a facile module-assisted radiosynthesis procedure...
August 31, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28862482/pseudoprogression-after-glioma-therapy-an-update
#13
Norbert Galldiks, Martin Kocher, Karl-Josef Langen
Initial diagnostics and follow-up of gliomas is usually based on contrast-enhanced MRI. However, the capacity of standard MRI to differentiate neoplastic tissue from posttherapeutic effects such as pseudoprogression is limited. Advanced neuroimaging methods may provide relevant additional information, which allow for a more accurate diagnosis especially in clinically equivocal situations. This review article focuses predominantly on PET using radiolabeled amino acids and advanced MRI techniques such as perfusion-weighted imaging (PWI) and summarizes the efforts of these methods regarding the identification of pseudoprogression after glioma therapy...
September 7, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28860608/fmiso-pet-derived-brain-oxygen-tension-maps-application-to-glioblastoma-and-less-aggressive-gliomas
#14
Ararat Chakhoyan, Jean-Sebastien Guillamo, Solène Collet, François Kauffmann, Nicolas Delcroix, Emmanuèle Lechapt-Zalcman, Jean-Marc Constans, Edwige Petit, Eric T MacKenzie, Louisa Barré, Myriam Bernaudin, Omar Touzani, Samuel Valable
Quantitative imaging modalities for the analysis of hypoxia in brain tumors are lacking. The objective of this study was to generate absolute maps of tissue ptO2 from [(18)F]-FMISO images in glioblastoma and less aggressive glioma patients in order to quantitatively assess tumor hypoxia. An ancillary objective was to compare estimated ptO2 values to other biomarkers: perfusion weighted imaging (PWI) and tumor metabolism obtained from (1)H-MR mono-voxel spectroscopy (MRS). Ten patients with glioblastoma (GBM) and three patients with less aggressive glioma (nGBM) were enrolled...
August 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28844925/case-study-multimodal-18-f-fluciclovine-pet-mri-and-ultrasound-guided-neurosurgery-of-an-anaplastic-oligodendroglioma
#15
Anna Karlberg, Erik Magnus Berntsen, Håkon Johansen, Mariane Myrthue, Anne Jarstein Skjulsvik, Ingerid Reinertsen, Morteza Esmaeili, Hong Yan Dai, Yiming Xiao, Hassan Rivaz, Per Borghammer, Ole Solheim, Live Eikenes
BACKGROUND: Structural MRI and histopathological tissue sampling are routinely performed as part of the diagnostic work-up of glioma patients. Due to the heterogeneous nature of gliomas, there is however a risk of undergrading caused by histopathological sampling errors. MRI has limitations in identifying tumor grade and type, detecting diffuse invasive growth, and separating recurrences from treatment induced changes. PET can provide quantitative information of cellular activity and metabolism, and may therefore complement MRI...
August 24, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28831534/comparison-of-18-f-fet-pet-and-perfusion-weighted-mri-for-glioma-grading-a-hybrid-pet-mr-study
#16
Antoine Verger, Christian P Filss, Philipp Lohmann, Gabriele Stoffels, Michael Sabel, Hans J Wittsack, Elena Rota Kops, Norbert Galldiks, Gereon R Fink, Nadim J Shah, Karl-Josef Langen
PURPOSE: Both perfusion-weighted MR imaging (PWI) and O-(2-(18)F-fluoroethyl)-L-tyrosine PET ((18)F-FET) provide grading information in cerebral gliomas. The aim of this study was to compare the diagnostic value of (18)F-FET PET and PWI for tumor grading in a series of patients with newly diagnosed, untreated gliomas using an integrated PET/MR scanner. METHODS: Seventy-two patients with untreated gliomas [22 low-grade gliomas (LGG), and 50 high-grade gliomas (HGG)] were investigated with (18)F-FET PET and PWI using a hybrid PET/MR scanner...
August 22, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28816956/differential-diagnosis-of-posterior-fossa-brain-tumors-multiple-discriminant-analysis-of-tl-spect-and-fdg-pet
#17
Moritaka Yamauchi, Tomohisa Okada, Tsutomu Okada, Akira Yamamoto, Yasutaka Fushimi, Yoshiki Arakawa, Susumu Miyamoto, Kaori Togashi
This study investigated the combined capability of thallium-201 (Tl)-SPECT and fluorine-18-fluoro-deoxy-glucose (FDG)-PET for differential diagnosis of posterior fossa brain tumors using multiple discriminant analysis.This retrospective study was conducted under approval of the institutional review board. In the hospital information system, 27 patients with posterior fossa intra-axial tumor between January 2009 and June 2015 were enrolled and grouped as the following 7 entities: low grade glioma (LGG) 6, anaplastic astrocytoma (AA) 2, glioblastoma (GBM) 3, medulloblastoma (MB) 3, hemangioblastoma (HB) 6, metastatic tumor (Mets) 3, and malignant lymphoma (ML) 4...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28805936/characterizing-hypoxia-in-human-glioma-a-simultaneous-multimodal-mri-and-pet-study
#18
Christine Preibisch, Kuangyu Shi, Anne Kluge, Mathias Lukas, Benedikt Wiestler, Jens Göttler, Jens Gempt, Florian Ringel, Mohamed Al Jaberi, Jürgen Schlegel, Bernhard Meyer, Claus Zimmer, Thomas Pyka, Stefan Förster
Hypoxia plays an important role for the prognosis and therapy response of cancer. Thus, hypoxia imaging would be a valuable tool for pre-therapeutic assessment of tumor malignancy. However, there is no standard validated technique for clinical application available yet. Therefore, we performed a study in 12 patients with high-grade glioma, where we directly compared the two currently most promising techniques, namely the MR-based relative oxygen extraction fraction (MR-rOEF) and the PET hypoxia marker H-1-(3-[(18) F]-fluoro-2-hydroxypropyl)-2-nitroimidazole ([(18) F]-FMISO)...
August 14, 2017: NMR in Biomedicine
https://www.readbyqxmd.com/read/28781923/discrepancy-between-radiological-and-histological-findings-in-ganglioglioma-of-the-optic-chasm-case-report
#19
Yoshito Sugita, Masahiro Sawada, Toshihiro Munemitsu, Tatsuya Higashi, Masato Hojo
BACKGROUND: Gangliogliomas involving the optic nerve or chiasm are extremely rare tumors, which can be confused radiologically with other neoplasms. α-[N-methyl-(11)C]-methylaminoisobutyric acid ((11)C-MeAIB) is a new artificial amino acid positron emission tomography (PET) tracer, which is metabolically more stable in vivo and may be more specific for tumors than (11)C-methionine. However, the utility of (11)C-MeAIB PET in the diagnosis of brain tumors has not yet been reported. CASE DESCRIPTION: A 26-year-old man presented with visual field defects and headache, and magnetic resonance imaging demonstrated a suprasellar mass involving the optic chiasm...
2017: Surgical Neurology International
https://www.readbyqxmd.com/read/28765227/determination-of-an-optimal-pharmacokinetic-model-of-18-f-fet-for-quantitative-applications-in-rat-brain-tumors
#20
Marie Anne Richard, Jérémie P Fouquet, Réjean Lebel, Martin Lepage
O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET) is a radiolabeled artificial amino acid used in PET for tumor delineation and grading. The present study compares different kinetic models to determine which are more appropriate for (18)F-FET in rats. Methods: Rats were implanted with F98 glioblastoma cells in the right hemisphere and scanned 9-15 d later. PET data were acquired during 50 min after a 1-min bolus of (18)F-FET. Arterial blood samples were drawn for arterial input function determination. Two compartmental pharmacokinetic models were tested: the 2-tissue model and the 1-tissue model...
August 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
84290
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"